See All Slides - tctmd.com

Slides

Presentation TCT 2019

Noble: Extended Follow-Up and Substudies

Presenter: Evald Christiansen

September 27, 2019

Presentation TCT 2019

ARC Initiative for Heart Failure and Shock: HF ARC, Shock ARC, and More

Presenter: Christopher O'Connor

September 27, 2019

Presentation TCT 2019

Devices for Heart Failure: FDA Perspectives on Trial Designs and Endpoints

Presenter: Bram Zuckerman

September 27, 2019

Presentation TCT 2019

Device-Related Thrombus: Mechanisms, Management, and Implications for Device Design

Presenter: Simon Cheung-chi Lam

September 27, 2019

Presentation TCT 2019

TAVR and Concomitant Atrial Fibrillation: Case Presentation

Presenter: Fabian Nietlispach

September 27, 2019

Debate: Dual Therapy (OAC+SAPT) Should Be the Default Therapy at Discharge in Most Patients - Pro: Dual Therapy (OAC+SAPT) Should Be the Default Therapy at Discharge in Most Patients

Presentation TCT 2019

Pro: Dual Therapy (OAC+SAPT) Should Be the Default Therapy at Discharge in Most Patients

Presenter: C. Michael Gibson

September 27, 2019

Presentation TCT 2019

Excel: Extended Follow-Up and Most Important Substudies

Presenter: Ori Ben-Yehuda

September 27, 2019

Presentation TCT 2019

Long-Term Safety of Drug-Coated Devices for Femoropopliteal Artery Revascularization: Updated Analysis of Medicare Beneficiary Data

Presenter: Eric Secemsky

September 27, 2019

Presentation TCT 2019

A Look Ahead for IVL

Presenter: Dean Kereiakes

September 27, 2019

Presentation TCT 2019

Update on Coronary IVL: Real-World Experiences

Presenter: Jonathan Hill

September 27, 2019

Advertisement

Slides

Noble: Extended Follow-Up and Substudies

ARC Initiative for Heart Failure and Shock: HF ARC, Shock ARC, and More

Devices for Heart Failure: FDA Perspectives on Trial Designs and Endpoints

Device-Related Thrombus: Mechanisms, Management, and Implications for Device Design

TAVR and Concomitant Atrial Fibrillation: Case Presentation

Pro: Dual Therapy (OAC+SAPT) Should Be the Default Therapy at Discharge in Most Patients

Excel: Extended Follow-Up and Most Important Substudies

Long-Term Safety of Drug-Coated Devices for Femoropopliteal Artery Revascularization: Updated Analysis of Medicare Beneficiary Data

A Look Ahead for IVL

Update on Coronary IVL: Real-World Experiences

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content